

## The Role of Upregulated *APOE* in Alzheimer's Disease Etiology

William K Gottschalk<sup>1</sup>, Mirta Mihovilovic<sup>1</sup>, Allen D Roses<sup>1,3</sup> and Ornit Chiba-Falek<sup>1,2\*</sup>

<sup>1</sup>Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA

<sup>2</sup>Center for Genomic and Computational Biology, Duke University Medical Center, Durham, NC 27710, USA

<sup>3</sup>Zinfandel Pharmaceuticals, Chapel Hill, NC, USA

The first and most firmly established genetic risk factor for sporadic late onset Alzheimer's disease (LOAD) is the  $\epsilon 4$  allele of the apolipoprotein E (*APOE*) gene [1]. Carrying the *APOE* $\epsilon 4$  variant significantly increases the lifetime risk for LOAD, with the number of copies present indicative of level of risk [1,2] and is associated with lower age of clinical disease onset [1,3-6]. Furthermore, genome-wide association studies (GWAS) for sporadic LOAD confirmed that *APOE* is the major susceptibility genomic region for the disease and reported significant associations with markers within the *APOE* linkage disequilibrium (LD) locus (contains *APOE*, *TOMM40* and *APOC1* genes). The strongest association signal (by wide margin) in these studies was found at the *APOE* LD region and no other LOAD-association in the human genome remotely approached the same level of significance [7-10]. However, the molecular mechanism underlying the reported genetic LOAD-associations with *APOE* LD region in general and *APOE* $\epsilon 4$  haplotype in particular has yet to be discovered.

It has been suggested that alteration of the expression levels of specific genes may be an important mechanism in the etiology of neurodegenerative disorders including LOAD [11]. Previously, using temporal and occipital tissues obtained from *APOE* $\epsilon 3/\epsilon 3$  donors we showed that *APOE*-mRNA levels are significantly increased in LOAD-affected brains compared to controls [12]. In preliminary studies, we performed expression analysis in cortical neurons from the temporal cortex of 3 LOAD patients and 3 normal controls isolated by laser capture microdissection (LCM) technique. We analyzed the *APOE*-mRNA counts relative to geometric mean of two housekeeping genes using the nCounter single cell gene expression technology and the nSolver program (NanoString). The results showed increased *APOE*-mRNA in LOAD compared to normal (our unpublished data) and validated our published findings obtained using homogenates of brain tissue for the expression analysis [12]. Our observation was consistent with other reports of elevated levels of *APOE*-mRNA in LOAD brains. For example, Zarow et al. report increased *APOE*-mRNA levels in the hippocampus of AD cases compared to controls [13] and Matsui et al. report increased *APOE*-mRNA levels in temporal cortex of AD donors compared to controls [14]. Furthermore, Akram et al. have demonstrated that *APOE*-mRNA and protein levels in the inferior temporal gyrus and the hippocampus are strongly, positively correlated with the progression of cognitive dysfunction [15].

A recent study showed that endoplasmic reticulum (ER)-mitochondrial communication and mitochondria associated ER membranes (MAM) function-as measured by the synthesis of phospholipids and of cholesteryl esters, respectively-are increased significantly in cells treated with *APOE* $\epsilon 4$ -containing astrocyte-conditioned media (ACM) as compared to those treated with *APOE* $\epsilon 3$ -containing ACM [16]. Upregulated MAM function was implicated in the pathogenesis of AD [17,18]. The new findings that *APOE* $\epsilon 4$  protein upregulates the activity of MAM may explain, in part, the contribution of *APOE* $\epsilon 4$  as a risk factor in the disease. Enhanced activity of *APOE* $\epsilon 4$  protein in correlation to AD-related cellular phenotypes has also been described previously. In human AD brain samples, amyloid deposits correlate with gene dosage of *APOE* $\epsilon 4$  [19], and *APOE* $\epsilon 4$  protein

more actively forms fibrils with  $A\beta$  protein than *APOE* $\epsilon 3$  *in vitro* [20]; moreover, *APOE* $\epsilon 4$  aggregates are themselves neurotoxic [21]. *APOE* $\epsilon 4$  is susceptible to cleavage of the C-terminus by cellular proteases, and the C-terminal fragments are cytotoxic, in part by eliciting intracellular neurofibrillary tangle formation and in part via disruption of mitochondrial and cytoskeletal functions [22-24]. *APOE* $\epsilon 4$  and *APOE* $\epsilon 3$  have different lipid-binding characteristics [25], contributing to greater  $A\beta$ -elicited lysosomal leakage and apoptosis in *APOE* $\epsilon 4$ -producing cells [26], and affecting the respective abilities of *APOE* $\epsilon 3$  and *APOE* $\epsilon 4$  to support neuronal maintenance and repair.

Interestingly, we showed that SNP rs429358, that defines the *APOE* $\epsilon 4$  haplotype, has a significant effect on *APOE*-mRNAs levels in temporal cortex obtain from LOAD cases. We demonstrated that the level of *APOE* mRNA was significantly higher in the *APOE* $\epsilon 3/\epsilon 3$  genotype group compared to *APOE* $\epsilon 3/\epsilon 4$ -genotype (Figure 1). In unpublished work, we measured *APOE*- mRNA levels in whole brains from humanized -*APOE* $\epsilon 3$  and -*APOE* $\epsilon 4$  homozygous mouse models generated by targeted replacement [27,28]. We found that human *APOE*-mRNA levels are >35% higher in brains of *APOE* $\epsilon 3$  homozygous mice compared to mice homozygotes to *APOE* $\epsilon 4$  (Figure 2). The analysis of humanized- *APOE* mice support the findings in LOAD-human brains, suggesting that while the effect of  $\epsilon 4$  variant is putatively on increased activity of the *APOE* protein, the effect of the  $\epsilon 3$  background is possibly executed via regulation of *APOE* gene expression that determines the steady state amount of the protein.


Different factors may regulate *APOE* gene expression including, but not limited to, genetic [12,29-31] and epigenetic [32] mechanisms. *Cis*-genetic variability on the background of the  $\epsilon 3$  haplotype contributes to differential *APOE* gene expression. We reported data showing that 523- polyT genotype, located upstream of *APOE* within the adjutant *TOMM40* locus, affects expression of genes in *APOE* LD region [12]. We demonstrated that the LOAD risk allele, very long ('VL'), is associated with increased levels of *APOE* transcripts in normal and LOAD-affected human brain tissues and with higher luciferase expression in a cell-based reporter system, compared to the short ('S') allele [12]. These observations provide a possible explanation for the genetic association of the 523-polyT locus with age of LOAD onset [33,34] and other disease related phenotypes [35-38]. Our observations were recently reproduced by Payton, et al. They showed that the shorter length poly-T

\*Corresponding author: Ornit Chiba-Falek, Department of Neurology, DUMC Box 2900, Duke University, Durham, North Carolina 27710, USA, Tel: 919 681-8001; E-mail: o.chibafalek@duke.edu


Received January 19, 2016; Accepted February 02, 2016; Published February 09, 2016

Citation: Gottschalk WK, Mihovilovic M, Roses AD, Chiba-Falek O (2016) The Role of Upregulated *APOE* in Alzheimer's Disease Etiology. J Alzheimers Dis Parkinsonism 6: 209. doi: 10.4172/2161-0460.1000209

Copyright: © 2016 Gottschalk WK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




**Figure 1: The effect of APOE haplotypes on APOE-mRNAs expression levels in human brain tissues from LOAD donors.** The study cohort consisted of brain (temporal and occipital cortex) tissues from Caucasian donors with LOAD. Subjects were genotyped for rs429358 and rs7412 SNPs to determine APOE status. Fold levels of human APOE mRNA were assayed in (A) temporal and (B) occipital tissues by real-time RT-PCR using TaqMan technology and calculated relative the geometric mean of GAPDH- and PPIA-mRNAs reference control using the 2<sup>-ΔΔCt</sup> method. The expression levels between e3/4 (rs429358-TC) and e3/3 (rs429358-TT) were compared. The values presented here are means levels ± SE adjusted for age, sex, PMI, and Braak and Braak stage.



**Figure 2: The effect of APOE haplotypes on human-APOE mRNAs expression levels in humanized mice brain tissues.** RNA was extracted from whole brain of three mice homozygotes for the human APOEe3 and three mice APOEe4 homozygous generated by targeted replacement<sup>28</sup>. Fold levels of human APOE mRNA were assayed in whole brain tissues by real-time RT-PCR using TaqMan technology and calculated relative the geometric mean of the mouse housekeeping genes, Gapdh- and Ppia- mRNAs reference control using the 2<sup>-ΔΔCt</sup> method. The expression levels between e4/4 and e3/3 were compared and the values presented here are means levels ± SE.

variants act as a repressor of luciferase gene expression in reporter gene constructs, whereas expression was reduced to approximately half of that observed for the 'VL variant [39].

Collectively the studies reviewed here suggest that up-regulated function of APOE due to either enhanced protein activity or increased APOE expression levels may contribute, in part, to the etiology of LOAD. Figure 3 summarizes our proposed model. While this model suggests the triggering event, the biochemical and cell biological pathways that mediate the consequences of this event are still being determined. Our perception of increased APOEe3 protein levels as a LOAD-pathogenic mechanism agrees with the concept that changes in expression levels of 'normal' protein in the brain can lead to neurodegenerative diseases. In conclusion, genetic heterogeneity across the APOE-LD region may lead, through different molecular mechanisms, to elevated ('pathogenic') ApoE function and possibly explains the extremely strong genetic association of the APOE-LD region with increased LOAD-risk and related phenotypes.



**Figure 3: A schematic model describing factors leading to upregulation of ApoE function and the impact on LOAD pathogenesis.**

## Funding

This work was funded in part by the National Institute on Aging (NIA) [R01AG040370 to AR].

## References

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261: 921-923.
2. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* 278: 1349-1356.
3. Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, et al. (2008) A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. *BMC Med Genomics* 1: 44.
4. Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, et al. (2007) Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/ marker association. *Genomics* 89: 655-665.
5. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, et al. (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. *Arch Neurol* 65: 45-53.
6. Waring SC, Rosenberg RN (2008) Genome-wide association studies in Alzheimer disease. *Arch Neurol* 65: 329-334.
7. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 41: 1088-1093.
8. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 41: 1094-1099.
9. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 45: 1452-1458.
10. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, et al. (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *J Clin Psychiatry* 68: 613-618.
11. Singleton A, Myers A, Hardy J (2004) The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. *Hum Mol Genet* 13: 123-126.
12. Linnertz C, Anderson L, Gottschalk W, Crenshaw D, Lutz MW, et al. (2014) The cis-regulatory effect of an Alzheimer's disease-associated poly-T locus on expression of TOMM40 and apolipoprotein E genes. *Alzheimers Dement* 10: 541-551.
13. Zarow C, Victoroff J (1998) Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. *Exp Neurol* 149: 79-86.
14. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, et al. (2007) Expression of APP pathway mRNAs and proteins in Alzheimer's disease. *Brain Res* 1161: 116-123.
15. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V (2012) Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. *Neurobiol Aging* 33: 628.
16. Tambini MD, Pera M, Kanter E, Yang H, Guardia-Laguarta C, et al. (2016) ApoE4 upregulates the activity of mitochondria-associated ER membranes. *EMBO Rep* 17: 27-36.
17. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, et al. (2012) Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. *EMBO J* 31: 4106-4123.
18. Schon EA, Area-Gomez E (2013) Mitochondria-associated ER membranes in Alzheimer disease. *Mol Cell Neurosci* 55: 26-36.
19. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, et al. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc Natl Acad Sci USA* 90: 9649-9653.
20. Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. *Am J Pathol* 145: 1030-1035.
21. Hatters DM, Zhong N, Rutenber E, Weisgraber KH (2006) Amino-terminal Domain Stability Mediates Apolipoprotein E Aggregation into Neurotoxic Fibrils. *J Mol Biol* 361: 932-944.
22. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekoni L, et al. (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. *Proc Natl Acad Sci U S A* 100: 10966-10971.
23. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, et al. (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. *Proc Natl Acad Sci U S A* 98: 8838-8843.
24. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, et al. (2005) Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. *Proc Natl Acad Sci U S A* 102: 18694-18699.
25. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, et al. (2000) Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. *Biochemistry* 39: 11657-11666.
26. Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, et al. (2002) Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. *J Biol Chem* 277: 21821-21828.
27. Sullivan PM, Mace BE, Maeda N, Schmechel DE (2004) Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. *Neuroscience* 124: 725-733.
28. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, et al. (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. *J Biol Chem* 272: 17972-17980.
29. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE (2010) APOE mRNAs and protein expression in postmortem brain are modulated by an extended haplotype structure. *Am J Med Genet B Neuropsychiatr Genet* 153B: 409-417.
30. Bekris LM, Lutz F, Yu CE (2012) Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. *J Hum Genet* 57: 18-25.
31. Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, et al. (2008) Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. *J Alzheimers Dis* 13: 255-266.
32. Yu CE, Cudaback E, Foraker J, Thomson Z, Leong L, et al. (2013) Epigenetic signature and enhancer activity of the human APOE gene. *Hum Mol Genet* 22: 5036-5047.
33. Roses AD (2010) An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. *Arch Neurol* 67: 536-541.
34. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, et al. (2010) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. *Pharmacogenomics J* 10: 375-384.
35. Bruno D, Nierenberg JJ, Ritchie JC, Lutz MW, Pomara N (2012) Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants. *Psychoneuroendocrinology* 37: 366-371.
36. Bruno D, Pomara N, Nierenberg J, Ritchie JC, Lutz MW, et al. (2012) Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants. *Exp Gerontol* 47: 347-352.
37. Hayden KM, McEvoy JM, Linnertz C, Attix D, Kuchibhatla M, et al. (2012) A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. *Alzheimers Dement* 8: 381-388.
38. Johnson SC (2011) The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOEepsilon3/epsilon3 genotype. *Alzheimers Dement* 7: 456-65.
39. Payton A, Sindrewicz P, Pessoa V, Platt H, Horan M, et al. (2015) A TOMM40 poly-T variant modulates gene expression and is associated with vocabulary ability and decline in nonpathologic aging. *Neurobiol Aging*.